Compare Stocks: KYMR, BIIB, ALNY, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$237.10 +0.2%	$262.62	$197.81 ▼ $495.55	$31.65B	0.3	2.00 million shs	1.85 million shs
BIIB Biogen	$218.50 -1.4%	$207.81	$131.52 ▼ $222.85	$32.73B	0.17	784,147 shs	517,409 shs
BNTX BioNTech	$102.07 -8.4%	$95.40	$79.52 ▼ $124.00	$28.17B	1.27	1.73 million shs	3.07 million shs
KYMR Kymera Therapeutics	$118.15 -1.7%	$112.78	$39.84 ▼ $130.05	$10.00B	1.95	692,836 shs	415,946 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-1.02%	+3.17%	-17.98%	-21.66%	-47.91%
BIIB Biogen	+0.19%	+3.34%	+7.73%	+13.01%	+62.44%
BNTX BioNTech	-1.03%	+0.46%	+20.50%	+16.10%	+8.14%
KYMR Kymera Therapeutics	-4.24%	-1.05%	+13.25%	+47.67%	+184.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$237.10 +0.2%	$262.62	$197.81 ▼ $495.55	$31.65B	0.3	2.00 million shs	1.85 million shs
BIIB Biogen	$218.50 -1.4%	$207.81	$131.52 ▼ $222.85	$32.73B	0.17	784,147 shs	517,409 shs
BNTX BioNTech	$102.07 -8.4%	$95.40	$79.52 ▼ $124.00	$28.17B	1.27	1.73 million shs	3.07 million shs
KYMR Kymera Therapeutics	$118.15 -1.7%	$112.78	$39.84 ▼ $130.05	$10.00B	1.95	692,836 shs	415,946 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-1.02%	+3.17%	-17.98%	-21.66%	-47.91%
BIIB Biogen	+0.19%	+3.34%	+7.73%	+13.01%	+62.44%
BNTX BioNTech	-1.03%	+0.46%	+20.50%	+16.10%	+8.14%
KYMR Kymera Therapeutics	-4.24%	-1.05%	+13.25%	+47.67%	+184.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.92	Moderate Buy	$386.14	62.86% Upside
BIIB Biogen	2.58	Moderate Buy	$227.79	4.25% Upside
BNTX BioNTech	2.74	Moderate Buy	$127.81	25.21% Upside
KYMR Kymera Therapeutics	2.88	Moderate Buy	$127.17	7.64% Upside

Current Analyst Ratings Breakdown

Latest KYMR, BIIB, ALNY, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$116.00 ➝ $151.00
8/25/2026	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$240.00 ➝ $260.00
8/25/2026	ALNY Alnylam Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$376.00
8/24/2026	KYMR Kymera Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$318.00
8/18/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$316.00 ➝ $256.00
8/13/2026	BIIB Biogen	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00
8/12/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/6/2026	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$135.00
8/6/2026	KYMR Kymera Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.54	$2.77 per share	85.48	$10.12 per share	23.43
BIIB Biogen	$9.89B	3.26	$22.36 per share	9.77	$127.56 per share	1.71
BNTX BioNTech	$3.25B	7.95	$1.21 per share	84.31	$81.64 per share	1.25
KYMR Kymera Therapeutics	$39.21M	250.55	N/A	N/A	$18.15 per share	6.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	44.07	24.57	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	38.67	13.58	6.89	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)

Latest KYMR, BIIB, ALNY, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
BNTX BioNTech	0.01	7.85	7.80
KYMR Kymera Therapeutics	N/A	10.34	10.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
BNTX BioNTech	15.52%
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
BNTX BioNTech	19.20%
KYMR Kymera Therapeutics	15.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
KYMR Kymera Therapeutics	170	83.15 million	69.86 million	Optionable

KYMR, BIIB, ALNY, and BNTX Headlines

Recent News About These Companies

20,000 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Bamco Inc. NY

August 28 at 3:05 AM | marketbeat.com

Wells Fargo & Company Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

August 27 at 9:59 AM | marketbeat.com

Proficio Capital Partners LLC Invests $1.27 Million in Kymera Therapeutics, Inc. $KYMR

August 27 at 6:16 AM | marketbeat.com

Boone Capital Management LLC Purchases Shares of 113,173 Kymera Therapeutics, Inc. $KYMR

August 27 at 4:24 AM | marketbeat.com

Kymera Therapeutics, Inc. $KYMR Stock Holdings Increased by Odyssean LLC

August 26 at 6:32 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 149,908 Kymera Therapeutics, Inc. $KYMR

August 26 at 4:07 AM | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Upgraded at TD Cowen

August 25 at 6:59 AM | marketbeat.com

Nicholas Investment Partners LP Invests $6.26 Million in Kymera Therapeutics, Inc. $KYMR

August 25 at 6:39 AM | marketbeat.com

Nan Fung Group Holdings Ltd Invests $3.54 Billion in Kymera Therapeutics, Inc. $KYMR

August 25 at 6:00 AM | marketbeat.com

5,538,210 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by BlackRock Inc.

August 24, 2026 | marketbeat.com

12,083 Shares in Kymera Therapeutics, Inc. $KYMR Bought by B. Metzler seel. Sohn & Co. AG

August 24, 2026 | marketbeat.com

Deutsche Bank AG Makes New $12.16 Million Investment in Kymera Therapeutics, Inc. $KYMR

August 23, 2026 | marketbeat.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Brokerages

August 21, 2026 | americanbankingnews.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 21, 2026 | marketbeat.com

Kymera Therapeutics (KYMR) Gets a Buy from J.P. Morgan

August 20, 2026 | theglobeandmail.com

Kymera Therapeutics (KYMR) Receives a Buy from Wells Fargo

August 20, 2026 | theglobeandmail.com

Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR

August 20, 2026 | marketbeat.com

Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR

August 18, 2026 | marketbeat.com

TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR

August 18, 2026 | marketbeat.com

Kymera Therapeutics, Inc. $KYMR Shares Sold by Bank of America Corp DE

August 18, 2026 | marketbeat.com

State of Wyoming Purchases New Position in Kymera Therapeutics, Inc. $KYMR

August 16, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR, BIIB, ALNY, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$237.10 +0.54 (+0.23%)

As of 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$218.50 -3.00 (-1.35%)

As of 04:00 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech NASDAQ:BNTX

$102.07 -9.33 (-8.38%)

As of 04:00 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Kymera Therapeutics NASDAQ:KYMR

$118.15 -2.08 (-1.73%)

As of 04:00 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYMR, BIIB, ALNY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYMR, BIIB, ALNY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYMR, BIIB, ALNY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR, BIIB, ALNY, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

BioNTech NASDAQ:BNTX

Kymera Therapeutics NASDAQ:KYMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYMR, BIIB, ALNY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYMR, BIIB, ALNY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYMR, BIIB, ALNY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR, BIIB, ALNY, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

BioNTech NASDAQ:BNTX

Kymera Therapeutics NASDAQ:KYMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools